keyboard_arrow_up

Biomarker Partnering Terms and Agreements Future and Market Deals

 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals

Biomarker partnering agreement structure

Biomarker partnering contract documents

Top biomarker deals by value

Most active biomarker dealmakers

 

Get a Sample of the Report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=56447.

 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 700 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2009. The chapter is organized by specific biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Get a Discount on the Report @ http://www.reportsnreports.com/contacts/Discount.aspx?name=56447.

 

In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

 

Biomarker Partnering Terms and Agreements includes:

Trends in biomarker dealmaking in the biopharma industry since 2009

Analysis of biomarker deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life biomarker deals

Access to several biomarker contract documents

The leading biomarker deals by value since 2009

Most active biomarker dealmakers since 2009

The leading biomarker partnering resources

 

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

 

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

 

Biomarker Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of biomarker deal trends since 2009

Access to headline, upfront, milestone and royalty data

Analysis of the structure of over 700 biomarker agreements with numerous real life case studies

Comprehensive access to over 50 actual biomarker contracts entered into by the world’s biopharma companies

Detailed access to actual biomarker contracts enter into by the leading fifty big pharma companies

Insight into the terms included in a biomarker agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Follow the below link to View Full Report with Table of Content

Complete report of 998 Pages is available @ http://www.reportsnreports.com/reports/56447-biomarker-partnering-terms-and-agreements.html.

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Biomarker Partnering Terms and Agreements” report OR for any other market research and intelligence needs you may have for your business.